Fall Tove, Mandic-Havelka Aleksandra, Helmersson-Karlqvist Johanna, Sundstrom Johan, Larsson Anders
Clin Lab. 2017 Sep 1;63(9):1493-1496. doi: 10.7754/Clin.Lab.2017.170412.
Fecal calprotectin measurement is generally recommended to exclude inflammatory bowel disease (IBD) in patients with suspected IBD. A problem with the fecal calprotectin assays so far has been the rather long test-turnaround times. Recently a particle enhanced turbidimetric immunoassay (PETIA) for fecal calprotectin with assay times of approximately 10 minutes has been introduced on the European market. The aim of this study was to define reference intervals for adults with this new fecal calprotectin PETIA using two different extraction methods.
Samples were collected from 382 healthy individuals from the Swedish CArdioPulmonary bioImage Study (SCAPIS) Uppsala cohort in the age range 50 - 65 years. 202 samples were processed with CALEX® Cap extraction device (BÜHLMANN, Schönenbuch, Switzerland) and 180 samples were extracted using weighed samples. The extracted samples were analyzed on a Mindray BS-380 using the fCal Turbo PETIA reagent (BÜHLMANN).
The calculated reference values for the Calex device were < 199 µg/g for the whole cohort, < 184 µg/g for females, and < 215 µg/g for males, while the corresponding values for weighed samples were < 153 µg/g for the whole cohort, < 141 µg/g for females, and < 215 µg/g for males. There were no significant statistical differences for calprotectin levels in males and females.
The CALEX device yielded slightly higher calprotectin values. As there were no significant gender differences, the study indicates gender independent reference intervals of < 199 µg/g feces for the CALEX device and < 153 µg/g feces for weighed samples in patients in the 50 - 65 year age range.
对于疑似炎症性肠病(IBD)的患者,通常建议检测粪便钙卫蛋白以排除IBD。目前粪便钙卫蛋白检测方法存在的一个问题是检测周转时间较长。最近,一种检测时间约为10分钟的粪便钙卫蛋白颗粒增强比浊免疫分析(PETIA)已在欧洲市场推出。本研究的目的是使用两种不同的提取方法确定采用这种新型粪便钙卫蛋白PETIA检测的成年人的参考区间。
从瑞典心肺生物影像研究(SCAPIS)乌普萨拉队列中年龄在50至65岁的382名健康个体中收集样本。202份样本使用CALEX®帽式提取装置(瑞士布赫曼公司,舍嫩布赫)进行处理,180份样本采用称重样本进行提取。使用迈瑞BS - 380和fCal Turbo PETIA试剂(布赫曼公司)对提取后的样本进行分析。
对于整个队列,使用CALEX装置计算出的参考值为<199μg/g,女性为<184μg/g,男性为<215μg/g;而称重样本的相应值分别为整个队列<153μg/g,女性<141μg/g,男性<215μg/g。男性和女性的钙卫蛋白水平无显著统计学差异。
CALEX装置产生的钙卫蛋白值略高。由于不存在显著的性别差异,该研究表明,对于年龄在50至65岁的患者,使用CALEX装置时,粪便中钙卫蛋白的性别独立参考区间为<199μg/g,称重样本为<153μg/g。